Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
277 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04228601 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 39 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT03417895 | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy(PASSION) | completed | Phase 2 | 59 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 |
| clinicaltrials |
| NCT06015048 | A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 364 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04842617 | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative | active not recruiting | Phase 3 | 5,274 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05751850 | HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 3 | 778 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 9, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | terminated | Phase 3 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04613674 | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | completed | Phase 3 | 441 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02989922 | A Study to Evaluate SHR-1210 in Subjects With Advanced HCC | completed | Phase 2 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03558191 | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | completed | Phase 2 | 156 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03711279 | A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 99 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06198556 | Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04842630 | A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 | 11 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03764293 | A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | completed | Phase 3 | 543 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Feb 6, 2024 | clinicaltrials |
| NCT03155425 | PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | completed | Phase 2 | 75 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06010680 | A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers | completed | Phase 1 | 6 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03099382 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | completed | Phase 3 | 457 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06123494 | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen | recruiting | Phase 3 | 360 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03472365 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | completed | Phase 2 | 67 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04624217 | A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05868057 | A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06093945 | Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03481998 | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 104 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06099990 | Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) | not yet recruiting | Phase 1 | 660 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Oct 25, 2023 | clinicaltrials |
| NCT06062355 | Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer | unknown | Phase 1 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Oct 2, 2023 | clinicaltrials |
| NCT03995472 | A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | completed | Phase 1 | 14 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04025957 | A Study of SHR-1501 in Patients With Advanced Tumors | completed | Phase 1 | 19 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05261646 | A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia | withdrawn | Phase 3 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Sep 28, 2023 | clinicaltrials |
| NCT04995042 | A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer | completed | Phase 1 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04346381 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | completed | Phase 2 | 233 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04367090 | Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | completed | Phase 1 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05353361 | A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | unknown | Phase 2 | 402 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04443751 | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06006104 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 49 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 23, 2023 | clinicaltrials |
| NCT05896020 | A Study of SHR-A1811 in Subjects With Gynaecologic Oncology | unknown | Phase 2 | 225 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05103826 | A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer | terminated | Phase 1 | 3 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04718740 | A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer | completed | Phase 1 | 33 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05074589 | Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer | completed | Phase 3 | 298 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04989829 | Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05046808 | Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects | completed | Phase 1 | 70 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04699968 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT03871855 | A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors | terminated | Phase 1 | 8 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05041920 | A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT04580498 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | unknown | Phase 2 | 107 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials